Plaintiff

Adapt Pharma Inc.

3 cases as plaintiff.

Cases
3
Active
0
3 closed
Filed
2016–2018
Top venue
D. New Jersey
3 cases

Company profile

Adapt Pharma Inc. / Adapt Pharma Operations Limited

Adapt Pharma is a specialty pharmaceutical company founded in 2014 by Seamus Mulligan and a small group of Irish pharma executives. It was headquartered in Dublin, Ireland, with U.S. headquarters in the Philadelphia suburbs (Radnor, Pennsylvania). It was privately held until Emergent BioSolutions Inc. (NYSE: EBS) acquired it in October 2018 for $635 million upfront ($575 million cash plus $60 million in Emergent stock) plus up to $100 million in sales-based milestones through 2022. At closing, Emergent took on roughly 50 Adapt employees in the U.S., Canada and Ireland. Adapt Pharma Operations Ltd., the Irish operating entity, reported revenue of about $134.9 million in its last full pre-acquisition year. Adapt is now a wholly owned Emergent subsidiary.

Products / operations. Adapt's business was built around naloxone, the opioid antagonist used to reverse overdose. Its sole marketed product was NARCAN (naloxone HCl) Nasal Spray 4 mg, which received FDA approval in November 2015 and launched commercially in early 2016 — the first FDA-approved needle-free nasal formulation of naloxone, and also approved in Canada (2016). Adapt licensed the underlying intranasal technology from Opiant Pharmaceuticals (formerly Lightlake Therapeutics) and sold Narcan primarily to first responders, state and local government purchasers, retail pharmacies and addiction treatment channels. The company also had a small pipeline of opioid-overdose and addiction treatment candidates. The entity asserting the patents here is an operating pharmaceutical business, not a non-practicing entity.

Patent-litigation posture. All three tracked cases are Hatch-Waxman ANDA infringement suits in which Adapt (with Opiant and its Adapt affiliates as co-plaintiffs) is the plaintiff and the generic filer is the defendant — consistent with the 3-plaintiff / 0-defendant counts. Venue is the District of New Jersey, not a plaintiff-friendly NPE venue.

Notable cases. Adapt Pharma Operations Ltd. v. Teva Pharmaceuticals USA, Inc. (D.N.J. 16-cv-07721, consolidated; second suit filed 2018 over the 2 mg product) concerned U.S. Patents 9,468,747, 9,561,177, 9,629,965, 9,775,838 and others. The district court invalidated the asserted claims as obvious (June 2020), and the Federal Circuit affirmed in February 2022 (25 F.4th 1354). Adapt Pharma Operations Ltd. v. Perrigo UK FINCO Limited Partnership (D.N.J. 18-cv-15287/16987) ended in a March 2020 consent judgment and license. Adapt/Opiant patents were also challenged via IPR petitions by Nalox-1 Pharmaceuticals LLC.

Keep this research.

Save to your free workspace, then choose whether to receive updates.

Adapt Pharma Operations Limited et al. v. Teva Pharmaceuticals USA, Inc. et al.

stayed
Docket:
2:18-cv-05752
Filed:
2018-04-09
Terminated:
2022-07-27

Hatch-Waxman/ANDA suit filed by Adapt Pharma and Opiant against Teva, triggered by Teva's Paragraph IV notice regarding ANDA No. 211561 for generic NARCAN 2 mg/spray. The case asserted U.S. 9,480,644 and U.S. 9,707,226. On July 28, 2020, the court stayed the case pending resolution of the related 4 mg Naloxone Case appeal; the final docket entry is dated July 27, 2022.

Adapt Pharma Operations Limited et al. v. Teva Pharmaceuticals USA, Inc. et al.

judgment (invalidity); affirmed on appeal
Docket:
2:16-cv-07721 (JLL)(JAD); 2:17-cv-00864; 2:17-cv-02877; 2:17-cv-05100; 2:18-cv-09880
Filed:
2016-11-26
Terminated:
2020-06-26

Adapt and Opiant sued Teva in D.N.J. asserting NARCAN naloxone nasal spray patents. The district court found the asserted patents invalid for obviousness on June 5, 2020, with judgment entered June 26, 2020; the Federal Circuit affirmed on Feb. 10, 2022. The '570 patent was not asserted but was cited as prior art (Wyse). Consolidated/related docket numbers included 2:17-cv-00864, 2:17-cv-02877, 2:17-cv-05100, 2:18-cv-09880; related Perrigo action 2:18-cv-15287.

Adapt Pharma Operations Limited et al. v. Perrigo UK FINCO Limited Partnership

related action
Docket:
2:18-cv-15287

Related Perrigo action in the D.N.J. NARCAN litigation; Perrigo UK FINCO Limited Partnership named as defendant. The '570 patent was not asserted; it was prior art (Wyse) in the related litigation.